Literature DB >> 15077310

Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study.

Elke Theander1, Rolf Manthorpe, Lennart T H Jacobsson.   

Abstract

OBJECTIVE: This study was undertaken to analyze standardized mortality ratios (SMRs) and causes and predictors of death in primary Sjögren's syndrome (SS) diagnosed according to 3 different classification criteria sets (the Copenhagen criteria, the European criteria, and the American-European consensus criteria (AECC).
METHODS: A linked registry study using information from the Malmö Primary SS Registry combined with the Swedish Cause-of-Death Registry was performed, and SMRs were calculated. Kaplan-Meier survival curves and log rank tests were used to compare survival probability between subgroups of patients with primary SS. Cox regression analysis was used to study the predictive value of various laboratory findings at the time of diagnosis.
RESULTS: Four hundred eighty-four patients with a median followup of 7 years (range 1 month to 17 years 11 months) were included. The SMR for those fulfilling the AECC (n = 265) was 1.17 (95% confidence interval [95% CI] 0.81-1.63). Thirty-four deaths occurred in this group of patients. Excess mortality was found only for lymphoproliferative malignancy (cause-specific SMR 7.89 [95% CI 2.89-17.18]), corresponding to 2.53 excess deaths per 1,000 person-years at risk. In those not fulfilling the AECC (n = 219), 14 deaths occurred, the SMR was 0.71 (95% CI 0.39-1.20), and no excess mortality due to any specific cause was found. Hypocomplementemia, defined as C3 and/or C4 values in the lowest quartile of the SS patients' values at the time of diagnosis, was a significant predictor of death, mainly due to lymphoproliferative malignancy.
CONCLUSION: No increased all-cause mortality could be detected for patients with primary SS compared with the general population. When subgroups of primary SS were compared, excess mortality due to lymphoproliferative malignancy was found in patients fulfilling the AECC, the strongest predictor for unfavorable outcome being low C3 and/or C4 levels at the time of diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077310     DOI: 10.1002/art.20176

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  55 in total

Review 1.  Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies.

Authors:  Abha G Singh; Siddharth Singh; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2015-09-27       Impact factor: 7.580

2.  Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors.

Authors:  E Theander; G Henriksson; O Ljungberg; T Mandl; R Manthorpe; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-11-10       Impact factor: 19.103

3.  Lymphocytic alveolitis: A surprising index of poor prognosis in patients with primary Sjogren's syndrome.

Authors:  Y A Dalavanga; P V Voulgari; A N Georgiadis; C Leontaridi; S Katsenos; M Vassiliou; A A Drosos; S H Constantopoulos
Journal:  Rheumatol Int       Date:  2005-12-13       Impact factor: 2.631

4.  Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome?

Authors:  Gintaras Sudzius; Diana Mieliauskaite; Almantas Siaurys; Rita Viliene; Irena Butrimiene; Dainius Characiejus; Irena Dumalakiene
Journal:  Rheumatol Int       Date:  2013-10-29       Impact factor: 2.631

5.  Primary Sjögren's syndrome and risk of ischemic stroke: a nationwide study.

Authors:  Chia-Hung Chiang; Chia-Jen Liu; Ping-Jen Chen; Chin-Chou Huang; Chien-Yi Hsu; Wan-Leong Chan; Po-Hsun Huang; Tzeng-Ji Chen; Shing-Jong Lin; Jaw-Wen Chen; Hsin-Bang Leu
Journal:  Clin Rheumatol       Date:  2014-03-21       Impact factor: 2.980

6.  Survival analysis of patients with Sjögren's syndrome in Turkey: a tertiary hospital-based study.

Authors:  Veli Yazisiz; Mesut Göçer; Funda Erbasan; İsmail Uçar; Bengisu Aslan; Şuayp Oygen; Edip Gökalp Gök; Mustafa Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2019-09-25       Impact factor: 2.980

7.  Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.

Authors:  Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-03       Impact factor: 4.794

8.  Multiple microlithiasis in bilateral parotid glands as the initial clinical manifestation of primary Sjögren's syndrome.

Authors:  Adrienn Dobai; Levente Pataky; József Barabás
Journal:  Oral Radiol       Date:  2017-06-12       Impact factor: 1.852

Review 9.  [Epidemiology of primary Sjörgren's syndrome].

Authors:  G Westhoff; A Zink
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

Review 10.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.